Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Through comparisons of genetics analyses of clinical case control studies with pathological case control studies of Alzheimer’s disease, this publication demonstrates that, at typical ages for case control studies (70-80 years), about 30% on clinically assigned cases are likely to be in the early stages of disease. This would suggest that Biomarker studies would need to take this into account when carrying out future case control comparisons.

Original publication

DOI

10.1016/j.neurobiolaging.2018.12.002

Type

Journal article

Publication Date

05/2019

Volume

77

Pages

178 - 182

Addresses

https://www.sciencedirect.com/science/article/pii/S0197458018304378?via%3Dihub

Keywords

Alzheimer, Genetics , Diagnosis, Biomarkers